MPM BioImpact’s 89bio ETNB Stock Holding History

MPM BioImpact’s Portfolio ETNB Stock Details ETNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-330,000	Closed	-$2.44M	–	48
2024 Q3	$2.44M	Sell	330,000 -791,736	-71%	-$6.66M	0.37%	41
2024 Q2	$8.99M	Buy	1,121,736 +153,994	+16%	+$1.38M	1.4%	27
2024 Q1	$11.3M	Buy	+967,742	New	+$10.7M	1.81%	21

Other funds holding ETNB

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

MPM BioImpact's ETNB Position: Q4 2024 in Review

MPM BioImpact sold out of 89bio (ETNB) in Q4 2024, closing a stake of 330,000 shares — an estimated $2.44M sold.

MPM BioImpact first reported a position in ETNB in Q1 2024 and held it in 3 quarters. The position peaked at $11.3M in Q1 2024. 155 funds tracked by Wall St. Rank hold ETNB as of Q4 2024.

MPM BioImpact reported no remaining 89bio position as of Q4 2024 after selling out during the quarter.
MPM BioImpact sold 330,000 89bio shares in Q4 2024, an estimated $2.44M.
MPM BioImpact first reported a position in 89bio in Q1 2024 and held it in 3 quarters.
MPM BioImpact's 89bio position peaked at $11.3M in Q1 2024.
155 funds tracked by Wall St. Rank held 89bio as of Q4 2024.

Based on MPM BioImpact's 13F filing for Q4 2024, filed 14 Feb 2025.